Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Trevi Therapeutics Inc TRVI

Healthcare Biotechnology
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TRVI)

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

PR Newswire 3 days ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

PR Newswire 10 days ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

PR Newswire 12 days ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

PR Newswire 12 days ago

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

PR Newswire February 27, 2025

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

PR Newswire February 25, 2025

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

PR Newswire January 30, 2025

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

PR Newswire January 8, 2025

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

PR Newswire December 16, 2024
View More News ››

Opinion & Analysis (NDAQ:TRVI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TRVI)

Trevi Therapeutics to Report Fourth Quarter and Year End 202

JUST IN: $TRVI Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March...
whytestocks - 10 days ago

Healthcare works in a recession

could see this sector rise
Tradinghands - 11 days ago

Using technical analysis for this one.

This stock is signalling strength to the upside this morning
coolfooldumbguy - 12 days ago

Trevi Therapeutics Announces Positive SSRE Outcome from Curr

JUST IN: $TRVI Trevi Therapeutics Announces Positive SSRE Outcome from Current Phase 2b CORAL Trial2024-12-12 09:19:46 ET DENVER, Colo.,...
whytestocks - December 12, 2024

Trevi Therapeutics, Inc. (TRVI): Advancing Haduvio for Chron

http://beyondspx.com/2024/08/02/trevi-therapeutics-inc-trvi-advancing-haduvio-for-chronic-cough-indications-with-robust-clinical-pipeline...
MikeTester - August 3, 2024
View more Bullboard ››

Falcon Gold Corp.

Falcon Gold Corp.

Falcon Gold Corp. is a Canada-based mineral exploration company focused on generating, acquiring, and exploring opportunities ...
View More »